Vanda falls 21% as tradipitant fails in phase 3 study for gastroparesis

Vanda Pharmaceuticals' (NASDAQ:VNDA) medicine tradipitant failed to beat placebo in a phase 3 trial to treat symptoms of gastroparesis.

The study, dubbed VP-VLY-686-3303, did not meet its main goal of showing a difference between the drug and placebo in changing the severity of nausea from baseline after 12 weeks of treatment.